Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY +3.19%72 Price-to-Free-Cash-Flow is 15.98 as of Aug. 19, 2026, which is 67% below its 10-year median of 47.98. GuruFocus rates CLPBY with a GF Score™ of 72/100 and a GF Value™ of $12.44 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 389 Medical Devices & Instruments companies, Coloplast AS ranks better than 71.72% on this metric.
As of today (2026-08-19), Coloplast AS's share price is $6.79.
Coloplast AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.43. Hence, Coloplast AS's Price-to-Free-Cash-Flow Ratio for today is 15.98.
The historical rank and industry rank for Coloplast AS's Price-to-Free-Cash-Flow or its related term are showing as below:
CLPBY'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.41 Med: 47.98 Max: 187.05
Current: 16.02
During the past 13 years, Coloplast AS's highest Price-to-Free-Cash-Flow Ratio was 187.05. The lowest was 14.41. And the median was 47.98.
CLPBY's Price-to-Free-Cash-Flow is ranked better than 71.72% of 389
companies
in the Medical Devices & Instruments industry
Industry Median: 24.3
vs CLPBY: 16.02
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Coloplast AS was 23.70% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -4.80% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 1.00% per year.
During the past 13 years, Coloplast AS's highest 3-Year average Free Cash Flow per Share Growth Rate was 44.10% per year. The lowest was -26.00% per year. And the median was 7.50% per year.
Coloplast AS (OTCPK:CLPBY) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Coloplast AS Price-to-Free-Cash-Flow Related Terms
Coloplast AS Price-to-Free-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Price-to-Free-Cash-Flow Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Price-to-Free-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Price-to-Free-Cash-Flow falls into.
Coloplast AS's Share Price of today is $6.79. Coloplast AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
What does a Price-to-Free-Cash-Flow of 15.98 mean?
Coloplast AS (CLPBY) has a Price-to-Free-Cash-Flow of 15.98 as of Aug. 19, 2026. Price-to-free-cash-flow ratio is the ratio of share price to a company's free cash flow per share. View historical data on Coloplast AS and its competitors. This is 67% below median its historical median of 47.98. Over the past decade, Coloplast AS's Price-to-Free-Cash-Flow has ranged from 14.41 to 187.05. According to the industry distribution chart, Coloplast AS ranks #110 out of 389 companies in the Medical Devices & Instruments industry, placing it in the top 28.3%.
Is Coloplast AS's Price-to-Free-Cash-Flow too high?
Coloplast AS's current Price-to-Free-Cash-Flow of 15.98 is 67% below median its 10-year median of 47.98. Over the past 10 years, this metric has ranged from a low of 14.41 to a high of 187.05. The Medical Devices & Instruments industry median Price-to-Free-Cash-Flow is 24.30. Coloplast AS's value of 15.98 is 34.2% below this industry median. Based on the distribution chart, Coloplast AS ranks #110 out of 389 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Price-to-Free-Cash-Flow compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #110 out of 389 companies for Price-to-Free-Cash-Flow. This puts Coloplast AS in the upper half of its industry. The industry median Price-to-Free-Cash-Flow is 24.30. Coloplast AS's value of 15.98 is 34.2% below this benchmark. Historically, Coloplast AS's own Price-to-Free-Cash-Flow has ranged from 14.41 to 187.05 over the past decade. While the company's 10-year median is 47.98 vs. the industry median of 24.30, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Free-Cash-Flow for a Medical Devices & Instruments company?
The median Price-to-Free-Cash-Flow among Medical Devices & Instruments companies is 24.30, based on 389 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Free-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Free-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Price-to-Free-Cash-Flow of 15.98 is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Free-Cash-Flow mean?
A high Price-to-Free-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-free-cash-flow ratio is the ratio of share price to a company's free cash flow per share. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Free-Cash-Flow is 24.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Price-to-Free-Cash-Flow is 15.98, which is 67% below median its own 10-year median of 47.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.44, compared to a current price of $6.79 — trading 45.4% below its estimated fair value. The current Price-to-Free-Cash-Flow is 15.98, which is 67% below median its 10-year median of 47.98 and 34.2% below the Medical Devices & Instruments industry median of 24.30. Coloplast AS's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Free-Cash-Flow calculated?
Price-to-Free-Cash-Flow is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Price-to-Free-Cash-Flow is 15.98 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.79 is trading 45.4% below its estimated GF Value™ of $12.44.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Price-to-Free-Cash-Flow: 15.98 (67% below median its 10-year median of 47.98)
GF Value™: $12.44 vs. price of $6.79 (45.4% below fair value)
Industry Position: 34.2% below the Medical Devices & Instruments median (#110 of 389)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBY
Price-to-Free-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
